Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Less than a year ago, Tilray (NASDAQ:TLRY) traded at an eye-popping $300 a share. But Sept. 19 is a long time ago in the cannabis investing world, as TLRY stock fell steadily since that time, closing yesterday at $35.70.

Here’s Why Beat-Down Tilray Stock Could Keep Dropping To As Low As $30

Cannabis stocks are getting high praise from Wall Street analysts lately, with several top companies landing new buy ratings.

Analyst Says Tilray Growth Expectations Are Way Too High

Cronos Group Inc (NASDAQ: CRON) and several other cannabis stocks have received some love from Wall Street analysts in the past week, but one analyst said Wednesday the 2019 struggles for Tilray Inc (NASDAQ: TLRY) will continue in the near term.

Analyst Likes Tilray In The Long Run, But Says Stock Is Overvalued Right Now

Cannabis company Tilray Inc. TLRY, +5.31% was initiated at Oppenheimer at a perform rating, with analyst Rupesh Parikh saying he believes shorter-term headwinds will offset longer-term positives.

Tilray started at a neutral rating at Oppenheimer; stock extends bounce

Aurora Cannabis

Canopy Growth

Cronos Group

Plunging share prices make it easy to fall into this trap.

The Biggest Mistake Marijuana Stock Investors Are Making Right Now

Major North American growers could lose business to lower-cost Colombian producers.

Why Colombia Poses a Threat to Cannabis Stocks

HEXO Corp

Village Farms International

Hemp provides the perfect opportunity to get infrastructure in place, if and when the U.S. government ever changes its tune on cannabis.

4 Canadian Pot Stocks Making the Legal Leap Into the U.S. Hemp Market

TLRY stock is a falling knife with a lot of downside momentum. A positive catalyst could end this downtrend, but there aren't any in sight.

There’s No Telling When Tilray Stock Will Find a Bottom

Corbus Pharmaceuticals Holdings

GW Pharmaceuticals

New Age Beverages

Zynerba Pharmaceuticals

The bottom line: a whole lot of uncertainty.

Here's What Last Week's FDA CBD Hearing Really Means for Cannabis Stocks

Aphria

Cara Therapeutics

Insys Therapeutics

Amplify Alternative Harvest ETF

Scotts Miracle-Gro

Should you put your hard-earned money into these stocks? We detail the investment opportunities, the risks, and regulations in the cannabis space.

Investing in Marijuana Stocks: Everything You Need to Know

Innovative Industrial Properties

Marijuana stocks were down Friday as the Food and Drug Administration began its first public hearing on CBD with a cautionary note.

Marijuana Stocks Fall As FDA Chief Sees 'Real Risks' In CBD Products

Much like Tilray stock holders, you can get rich with tiny marijuana stocks -- at the very beginning -- if you know what you're doing.

The Next Tilray Stock Is Just Around the Corner

Within the burgeoning cannabis sector, CBD stocks present massive upside potential for their underlying utility and wide appeal.

CBD Stocks to Buy for Mainstream Marijuana Profits

There are plenty of marijuana stocks to buy these days. However, these three could be the only ones really worth it for the long haul.

The Only 3 Marijuana Stocks You Need to Own

Tilray sees marijuana evolving into a branded market of edibles, oils, medicines and flavorings, as shortages become gluts. Watch TLRY stock.

Tilray Stock Keeps Its Eyes on the Future

MedMen Enterprises Inc.

Here's why these cannabis stocks have been sliding while the rest of the industry is in positive territory.

The 3 Worst Marijuana Stocks of 2019 So Far

America's most popular professional sport plans to research the medical buzz surrounding pot.

Hut. Hut. High! The NFL to Consider Marijuana as a Possible Pain Management Tool

Tilray stock doesn't look that healthy, as it's trapped in a painful downtrend. Until that changes, avoid TLRY stock on the long side.

Why Investors Shouldn’t Buy Tilray Stock Right Now

Following a long, steep correction and on the heels of earnings, there’s less to fear in stepping into a contrarian position in Tilray stock.

How and Why Tilray Stock Is a Buy Here

CannTrust Holdings

Greenlane Holdings

Nasdaq

Nearly a dozen marijuana stocks are now listed side by side with time-tested businesses on reputable U.S. exchanges.

11 Pot Stocks Now Listed on the NYSE or Nasdaq

Trulieve Cannabis Corp.

Despite weaker-than-expected cannabis sales in Canada, some big pot stocks have increasing EPS projections.

4 Billion-Dollar Marijuana Stocks With Rising Profit Estimates

TLRY still hasn't managed to turn things around. And TLRY stock price could slump even farther this summer.

Tilray Stock Still Hasn’t Bottomed

Tilray, Inc. announced Thursday that its wholly owned subsidiary Tilray Portugal Unipessoal Lda.

Tilray Boosts Export Capability With EU Manufacturing License, GMP Certification

Tilray Inc. said its Portugal-based wholly-owned subsidiary, Tilray Portugal Unipessoal Lda. has received a Good Manufacturing Practices (GMP) certification and a standard manufacturing license

Tilray's Portugal sub receives GMP certification for export of dried cannabis

Novartis

Speaking with CNBC's Jim Cramer from the "Healthy Returns" conference in New York City, Novartis CEO Vas Narasimhan says cannabis is "not a focus" for the pharma company.

News for Tilray Brands Stock (TLRY)